Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Short-term Investments: 2013-2024

Historic Short-term Investments for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $360.0 million.

  • Ptc Therapeutics' Short-term Investments rose 108.31% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 108.31%. This contributed to the annual value of $360.0 million for FY2024, which is 27.32% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Short-term Investments of $360.0 million as of FY2024, which was up 27.32% from $282.7 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Short-term Investments peaked at $894.8 million during FY2020, and registered a low of $130.9 million during FY2022.
  • Its 3-year average for Short-term Investments is $257.9 million, with a median of $282.7 million in 2023.
  • Per our database at Business Quant, Ptc Therapeutics' Short-term Investments soared by 124.53% in 2020 and then plummeted by 77.58% in 2022.
  • Ptc Therapeutics' Short-term Investments (Yearly) stood at $894.8 million in 2020, then crashed by 34.78% to $583.7 million in 2021, then slumped by 77.58% to $130.9 million in 2022, then skyrocketed by 116.04% to $282.7 million in 2023, then increased by 27.32% to $360.0 million in 2024.